首页> 美国卫生研究院文献>Case Reports in Medicine >Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism
【2h】

Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism

机译:英夫利昔单抗致甲状腺功能减退:一种新的病例和有关机制的假设。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report a patient with cutaneous sarcoidosis who developed hypothyroidism following 17 months of infliximab therapy. To our knowledge, this is the first reported case of hypothyroidism following infliximab administration. While it is possible that the patient's hypothyroidism was unrelated to the use of infliximab, the time course and lack of alternative explanations make such an association plausible. We postulate that hypothyroidism in this patient may have been related to the development of autoantibodies to infliximab that triggered the development of an autoimmune thyroiditis. Regardless of the mechanism, we would encourage clinicians to keep the potential mechanisms of TNF-α in mind when treating patients with TNF-α antagonist medications.
机译:我们报道了英夫利昔单抗治疗17个月后出现甲状腺功能减退的皮肤结节病患者。据我们所知,这是英夫利昔单抗给药后首次报告甲状腺功能减退的病例。尽管患者的甲状腺功能减退可能与英夫利昔单抗的使用无关,但时间进程和缺乏其他解释使得这种关联似乎合理。我们假设该患者的甲状腺功能减退可能与英夫利昔单抗自身抗体的发展有关,后者触发了自身免疫性甲状腺炎的发展。无论采用哪种机制,我们都鼓励临床医生在用TNF-α拮抗剂药物治疗患者时牢记TNF-α的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号